Earnings Outlook For NeuroPace
NeuroPace (NASDAQ:NPCE) is preparing to release its quarterly earnings on Tuesday, 2026-03-03. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect NeuroPace to report an earnings per share (EPS) of $-0.15.
Anticipation surrounds NeuroPace's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Historical Earnings Performance
The company's EPS beat by $0.09 in the last quarter, leading to a 38.09% increase in the share price on the following day.
Here's a look at NeuroPace's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.20 | -0.23 | -0.24 | -0.22 |
| EPS Actual | -0.11 | -0.26 | -0.21 | -0.18 |
| Price Change % | 38.09 | 2.08 | 20.46 | -2.43 |
NeuroPace Share Price Analysis
Shares of NeuroPace were trading at $14.58 as of February 27. Over the last 52-week period, shares are up 19.13%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
Unveiling the Story Behind NeuroPace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
NeuroPace: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: NeuroPace displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 29.89%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NeuroPace's net margin excels beyond industry benchmarks, reaching -12.78%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): NeuroPace's ROE excels beyond industry benchmarks, reaching -18.42%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): NeuroPace's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.28% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: NeuroPace's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.84, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
To track all earnings releases for NeuroPace visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.